Erratum to: Safety and tolerability of AZD8055 in Japanese patients with advanced solid tumors; a dose-finding phase I study

Hajime Asahina · Hiroshi Nokihara ·
Noboru Yamamoto · Yasuhide Yamada ·
Yosuke Tamura · Kazunori Honda · Yoshitaka Seki ·
Yuko Tanabe · Hitoshi Shimada · Xiaojin Shi ·
Tomohide Tamura

Published online: 5 September 2012
© Springer Science+Business Media, LLC 2012

Erratum to: Invest New Drugs DOI 10.1007/s10637-012-9860-4

An error occurred in processing the original article: Figure 1b was reproduced in place of Figure 1a. The correct Figure 1 is shown below.

The online version of the original article can be found at <http://dx.doi.org/10.1007/s10637-012-9860-4>.

H. Asahina · H. Nokihara · N. Yamamoto · Y. Tamura ·
K. Honda · Y. Seki · Y. Tanabe · T. Tamura (✉)
Division of Internal Medicine and Thoracic Oncology,
National Cancer Center Hospital,
Tsukiji 5-1-1, Chuo-ku,
Tokyo 104-0045, Japan
e-mail: ttamura@ncc.go.jp

Y. Yamada
Division of Gastrointestinal Oncology,
National Cancer Center Hospital,
Tokyo, Japan

H. Shimada · X. Shi
Research and Development, AstraZeneca KK,
Osaka, Japan

Fig. 1 Geometric mean plasma concentrations of AZD8055 versus time following a single dose (a) and at steady state (b)